



# SUVEN Life Sciences

**Communication to investors**

**Mar 2019**

25-May-19

*2018-19 Q4 results*



# Risk statement

Except for historical information, all of the statements, expectations and assumptions, including expectations and assumptions, contained in this presentation may be forward-looking statements that involve a number of risks and uncertainties. Although Suven attempts to be accurate in making these forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based. Other important factors which could cause these statements to differ materially including outsourcing trends, economic conditions, dependence on collaborative partnership programs, retention of key personnel, technological advances and continued success in growth of sales that may make our products/services offerings less competitive; Suven may not undertake to update any forward-looking statements that may be made from time to time.

# FINANCIAL QUICK VIEW

## Quarter 4 – Mar 2019



- Growth in income 90.72%
- Growth in Pre-R&D EBIDTA 129.13%
- Growth in EBIDTA 163.66%
- Growth in PAT 170.41%
- R&D cost on revenue 6.95%
- Increase in R&D costs 27.35%

# FINANCIAL QUICK VIEW

## Year ending – Mar 2019



• Growth in income	6.05%
• Growth in Pre-R&D EBIDTA	-2.10%
• Growth in EBIDTA	-3.29%
• Growth in PAT	-5.20%
• R&D cost on revenue	8.76%
• Increase in R&D costs	3.09%







# MAJOR PROFITABILITY RATIOS

	Q4 Mar 19	FY Mar 19
Pre-R&D EBITDA to Income	49.37%	44.79%
EBIDTA to Income	42.42%	36.03%
PAT to Income	26.47%	21.80%
Cash Flow to Income	28.60%	25.02%



# Q4 to Q3 COMPARISON


Current quarter to previous quarter





# INCOME COMPARISON

Year on year




25-May-19

2018-19 Q4 results



# PROFIT COMPARISON

Year on year



25-May-19

2018-19 Q4 results





# EBIDTA COMPARISON

Year on year




25-May-19

2018-19 Q4 results



# R & D – EXPENDITURE

Year on year




25-May-19

2018-19 Q4 results



# PRE-R&D EBIDTA

Year on year




25-May-19

2018-19 Q4 results



# PRE-R&D CASHFLOW

Year on year



25-May-19

2018-19 Q4 results

# Financial Snapshot



All figures are in INR Million, other than ratios and EPS

	Q4 - FY19	Q3 - FY19	Q4 - FY18	Standalone		Consolidated	
				2018-19	2017-18	2018-19	2017-18
Income	2,571	1,348	2,229	6,877	6,485	6,877	6,485
Pre-R&D EBITDA	1,269	554	1,174	3,080	3,147	3,045	3,117
Pre-R&D EBITDA Margin	49.37%	41.10%	52.65%	44.79%	48.52%	44.28%	48.06%
EBITDA	1,090	414	1,005	2,478	2,562	1,847	2,215
EBITDA Margin	42.42%	30.69%	45.06%	36.03%	39.50%	26.85%	34.15%
EBIT	1,037	357	949	2,255	2,346	1,624	1,999
EBIT Margin	40.32%	26.47%	42.57%	32.79%	36.17%	23.61%	30.82%
Financing costs	16	5	13	38	46	38	46
Taxes	340	100	313	718	718	718	718
Taxes to Profit	33.34%	28.41%	33.47%	32.38%	31.24%		
Net Profit after tax	680	252	623	1,499	1,582	868	1,234
NP Margin	26.47%	18.67%	27.95%	21.80%	24.39%	12.62%	19.03%
EPS (basic & diluted not annualised)	5.34	1.98	4.91	11.79	12.45	6.83	9.72
Paid up share capital (One Rupee Share)	127	127	127	127	127	127	127
Depreciation	55	56	54	221	213	221	213
R&D expenses	179	140	169	603	585	1,199	902

On consolidation of the accounts of Suven Neurosciences, Inc., USA, the wholly owned subsidiary, the PAT reduced to INR 868 Mn and expenditure on R&D increased to INR 1199 Mn..

25-May-19

2018-19 Q4 results



# News Release

- Marupirdine (SUVN-502) Phase 2A clinical trial, indicated for patients with moderate Alzheimer's initiated in 76 investigator sites in USA and completed clinical trial with the last patient last visit (LPLV) in May 2019.
- Top-line Phase 2A data for Masupirdine (SUVN-502) is on track to be presented at Alzheimer's Association International Conference at Los Angeles on 17<sup>th</sup> July 2019.
- During the period Suven secures 12 product patents in Eurasia, Europe, India, Israel, Japan, Macao, Mexico, New Zealand, Sri Lanka, South Korea.
- Suven invested through Suven Pharma, Inc., taking minority stake in Shore Suven Pharma, Inc., USA.